Business Description
Belite Bio Inc
NAICS : 325412
SIC : 2834
Share Class Description:
FRA:D01: ADRDescription
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.97 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -70.4 | |||||
| 3-Year EPS without NRI Growth Rate | -70.8 | |||||
| 3-Year FCF Growth Rate | -82.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 22.91 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.3 | |||||
| 9-Day RSI | 36.87 | |||||
| 14-Day RSI | 41.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.04 | |||||
| ROA % | -40.8 | |||||
| ROIC % | -53.41 | |||||
| 3-Year ROIIC % | -446.51 | |||||
| ROC (Joel Greenblatt) % | -56.05 | |||||
| ROCE % | -42.72 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 12.97 | |||||
| Price-to-Tangible-Book | 12.91 | |||||
| EV-to-EBIT | -38 | |||||
| EV-to-Forward-EBIT | -27.31 | |||||
| EV-to-EBITDA | -38 | |||||
| EV-to-FCF | -46.79 | |||||
| Price-to-Net-Current-Asset-Value | 13.48 | |||||
| Earnings Yield (Greenblatt) % | -2.63 | |||||
| FCF Yield % | -2.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Belite Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.131 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 41.85 | ||
| 14-Day ATR (€) | 1.096325 | ||
| 20-Day SMA (€) | 43.55 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 29.5 - 46.4 | ||
| Shares Outstanding (Mil) | 30.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Belite Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Belite Bio Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Belite Bio Inc Frequently Asked Questions
What is Belite Bio Inc(FRA:D01)'s stock price today?
The current price of FRA:D01 is €43.00. The 52 week high of FRA:D01 is €46.40 and 52 week low is €29.50.
When is next earnings date of Belite Bio Inc(FRA:D01)?
The next earnings date of Belite Bio Inc(FRA:D01) is 2024-11-14 Est..
Does Belite Bio Inc(FRA:D01) pay dividends? If so, how much?
Belite Bio Inc(FRA:D01) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers